Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Robert Pattinson claims he's a pathological liar. What 'The Drama' star has said about his 'shtick' - 2Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- 3Germany records first wolf bite on human since repopulation
- 4An Ideal Getaway - Spots for Solo Travel
- 5Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- What's going around right now? COVID, flu, stomach bug on the rise
- Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- Investigate Something else for Less: Financial plan Travel Objections
- Believe Should Unwind? Look at These Scaled down Games
- Israel issues notice that Ben-Gurion Airport flights likely restricted until at least April 16
- From Iran to Israel: An Iranian volunteer’s unlikely stand in wartime
- Starbucks' new 'Bearista' cup is causing a stir — and is being listed on eBay for $600
- Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
